Unlocking Potential. Faster.

Advancing assets with differentiated upside potential and unique commercial advantages

CITIUS PHARMA

FACT SHEET
SUMMER 2021

CORPORATE OVERVIEW

Citius Pharmaceuticals, Inc. (Citius) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a diversified pipeline of anti-infectives in adjunct cancer care, stem cell therapy and unique prescription products. Three of its four pipeline candidates would be the first and only prescription treatments in their indications, if approved by the FDA. A Phase 3 pivotal superiority trial is currently underway for its lead product candidate, Mino-Lok®, an antibiotic lock solution to salvage infected central venous catheters (CVCs) of patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok® was granted Fast Track designation by the FDA and would be the first and only FDA-approved treatment to salvage infected CVCs. Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell (*i*-MSC) treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions. Citius's two additional product candidates are Halo-Lido, potentially the first and only FDA-approved prescription treatment for hemorrhoids, and Mino-Wrap, potentially the first and only FDA-approved product to prevent infection in tissue expanders and breast implants post mastectomy.

Anticipated near-term catalysts

- **Mino-Lok NDA submission est. 2022**
- **Halo-Lido Phase 2b trial start est. Q4 2021**
- **NC *i*-MSC IND filing est. 2022**
- **Mino-Wrap IND filing est. 2022**

NASDAQ: CTXR

Share Price	**$2.75 (6/14/21)**
52-Wk. Range	**$0.78-$2.90**
Avg. Vol.	**6.3M**
Shares O/S	**134.7M (3/31/21)**
Market Cap	**$394M**

INVESTMENT HIGHLIGHTS

Advancing Four Programs: "First and Only" Market Potential

- Mino-Lok® (Phase 3): potential to be the ***first and only*** FDA-approved product to salvage infected central venous catheters (CVCs)
- NC *i*-MSC: novel stem cell therapy for acute respiratory distress syndrome (ARDS), for which there is no FDA-approved drug therapy available
- Halo-Lido: potential to be the ***first and only*** FDA-approved prescription therapy for hemorrhoids
- Mino-Wrap: potential to be the ***first and only*** FDA-approved product to prevent infections associated with post mastectomy breast implants

Multi-billion Global Market Opportunities

- Attractive diversified multibillion-dollar opportunities in adjunctive cancer care, infectious and gastrointestinal diseases
- CRBSI and central line-associated bloodstream infection (CLABSI) market total estimated at $1.8B worldwide
- ARDS market large with no approved therapies
- Tissue expander infection prevention market est. $400M worldwide
- Prescription hemorrhoid market est. >$2B US

Seasoned Leadership

- Extensive pharma operational and financial track record
- Scientific Advisory Board of leading KOLs in infectious disease, pulmonology (ARDS), breast surgery
- Multibillions of dollars in successfully completed transactions for numerous companies

Strong Financial Platform

- Cash runway into 2023 ($103.7M cash as of 3/31/21)
- Management fully committed with $26.5 million invested by founders

LEADERSHIP

Leonard Mazur, EXECUTIVE CHAIRMAN, DIRECTOR
Myron Holubiak, PRESIDENT AND CHIEF EXECUTIVE OFFICER
Jamie Bartushak, EVP AND CHIEF FINANCIAL OFFICER
Dr. Myron Czuczman, EVP AND CHIEF MEDICAL OFFICER
Gary Talarico, EVP, OPERATIONS
Dr. Alan Lader, VP, CLINICAL OPERATIONS
Ilanit Allen, VP, INVESTOR RELATIONS

RECENT NEWS

- Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
- Citius Pharmaceuticals Added to Russell 2000® Index
- Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting

PIPELINE: FOUR ACTIVE PROGRAMS

PROGRAM	INVESTIGATIONAL INDICATION	ESTIMATED MARKET (WW)	PRECLINICAL	PHASE I	PHASE II	PHASE III	ANTICIPATED MILESTONES
MINO-LOK®	TREAT CVC INFECTIONS	> $1.8B					• NDA 2022
HALO-LIDO (CITI-002)	RX THERAPY FOR HEMORRHOIDS	> $2B					• IND 2021 • Ph 2b 2021
MINO-WRAP (CITI-101)	PREVENT INFECTIONS ASSOCIATED WITH BREAST IMPLANTS	> $400M					• IND 2022
NC *i*-MSC (CITI-401)	TREAT ARDS	Multi-billion					• IND 2022

MINO-LOK®

In late-stage development, Mino-Lok® is potentially the first and only antibiotic lock solution under investigation to salvage infected central venous catheters (CVCs) causing catheter-related bloodstream infections. Citius believes Mino-Lok® provides a superior alternative to removing and replacing a CVC, leading to a reduction in serious adverse events and cost savings to the healthcare system. A multicenter Phase 3 pivotal superiority trial is currently underway. Citius licensed the worldwide rights to Mino-Lok® from The University of Texas MD Anderson Cancer Center.

HALO-LIDO

Halo-Lido (CITI-002) is a topical formulation of halobetasol and lidocaine designed to provide anti-inflammatory and anesthetic symptomatic relief to people with hemorrhoids. There are no FDA-approved prescription products on the market to treat hemorrhoids, and Citius's formulation could become the first FDA-approved prescription product to treat hemorrhoids in the United States. Citius expects to submit an investigational new drug application (IND) for Halo-Lido in the third quarter of 2021 with a Phase 2b clinical trial estimated to begin in the fourth quarter of 2021.

NC *i*-MSC (Stem Cells)

Preclinical activities are underway for Citius's unique, proprietary stem cell therapy for an initial indication in the treatment of Acute Respiratory Distress Syndrome (ARDS). Compared with donor-derived cells that require a continuous supply of new donors, Citius believes its induced mesenchymal stem cells (*i*-MSCs), derived from a single clonal induced pluripotent stem cell (iPSC), offer multiple advantages including consistent and scalable manufacturing and a potentially limitless supply. Positive interim results from a proof-of-concept study demonstrate a marked improvement in *i*-MSC-treated animals over control animals in key clinical parameters. Currently, there is no FDA-approved drug therapy available for ARDS. Citius expects to file an IND in 2022.

Mino-Wrap

Mino-Wrap (CITI-101) is a novel therapeutic designed to significantly reduce the rate of infection in post-mastectomy breast cancer patients that elect to undergo reconstructive breast surgery. This liquefying gel-based wrap provides inflammatory tissue protection and prevents infection in tissue expanders and breast implants post mastectomy. Mino-Wrap, licensed from MD Anderson Cancer Center, has the potential to be the first and only FDA-approved product for this indication. Citius targets filing an IND for Mino-Wrap in 2022.

Citius Pharmaceuticals, Inc.

11 Commerce Drive, First Floor
Cranford, NJ 07016
www.citiuspharma.com

CITIUS PHARMA

Investor Relations Contact

Ilanit Allen
(908) 967-6677 x113
iallen@citiuspharma.com